Rise Advisors’s Allogene Therapeutics ALLO Stock Holding History

Rise Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-827	Closed	-$1.02K	–	155
2025 Q3	$1.02K	Buy	+827	New	+$986	﹤0.01%	1281

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Rise Advisors's ALLO Position: Q4 2025 in Review

Rise Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2025, closing a stake of 827 shares — an estimated $1.02K sold.

Rise Advisors first reported a position in ALLO in Q3 2025 and held it in 1 quarter. The position peaked at $1.02K in Q3 2025. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

Rise Advisors reported no remaining Allogene Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 827 Allogene Therapeutics shares in Q4 2025, an estimated $1.02K.
Rise Advisors first reported a position in Allogene Therapeutics in Q3 2025 and held it in 1 quarter.
Rise Advisors's Allogene Therapeutics position peaked at $1.02K in Q3 2025.
172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.